Director/PDMR Shareholding

15 December 2017 12:00 GMT



Disclosure under Article 19 of the EU Market Abuse Regulation 


AstraZeneca PLC (the Company) announces that, on 14 December 2017, it was notified by Pascal Soriot, a Director of the Company, that, on 13 December 2017, Mr Soriot ceased to be beneficially interested in 40,148 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

1    Details of the person discharging managerial responsibilities / person   closely associated   
a)    Name      Pascal   Soriot   
2    Reason for the notification   
a)    Position/status    Chief   Executive Officer 
b)    Initial notification /Amendment      Initial   notification 
3    Details of the issuer, emission allowance market participant, auction   platform, auctioneer or auction monitor   
a)    Name      AstraZeneca   PLC 
b)    LEI      PY6ZZQWO2IZFZC3IOL08 
4    Details of the transaction(s): section to be repeated for (i) each   type of instrument; (ii) each type of transaction; (iii) each date; and (iv)   each place where transactions have been conducted     
a)    Description of the financial instrument, type of instrument Identification   code       Ordinary Shares of US$0.25 each in AstraZeneca PLCGB0009895292
b)    Nature of the transaction      Gift   of shares to family members for nil consideration 
c)    Price(s) and volume(s)      Price(s)    Volume(s) 
0  40,148   
d)    Aggregated information   - Aggregated volume - Price    Not applicable - single transaction
e)    Date of the transaction      13   December 2017 
f)    Place of the transaction      Outside   a trading venue 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.   


For more information, please visit and follow us on Twitter @AstraZeneca.


Media Relations 
Esra   Erkal-Paler  UK/Global  +44 203 749 5638 
Karen   Birmingham  UK/Global  +44 203 749 5634 
Rob Skelding  UK/Global  +44 203 749 5821 
Matt   Kent  UK/Global  +44 203 749 5906 
Gonzalo   Viña  UK/Global  +44 203 749 5916 
Jacob   Lund  Sweden  +46 8 553 260 20 
Michele   Meixell  US  +1 302 885 2677 
Investor Relations 
Thomas Kudsk Larsen       +44 203 749 5712 
Craig Marks  Finance,   Fixed Income, M&A  +44 7881 615 764 
Henry Wheeler  Oncology  +44 203 749 5797 
Mitchell Chan  Oncology;   Other  +1 240 477 3771 
Christer Gruvris  Brilinta; Diabetes  +44 203 749 5711 
Nick Stone  Respiratory;   Renal  +44 203 749 5716 
US toll free  +1 866 381 7277 


Adrian Kemp
Company Secretary

AstraZeneca PLC 

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links